Immunome, Inc. (NASDAQ:IMNM) Shares Bought by Magnus Financial Group LLC

Magnus Financial Group LLC lifted its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 107.8% during the fourth quarter, Holdings Channel reports. The firm owned 53,536 shares of the company’s stock after buying an additional 27,777 shares during the period. Magnus Financial Group LLC’s holdings in Immunome were worth $569,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in IMNM. JPMorgan Chase & Co. grew its stake in Immunome by 6.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock worth $359,000 after buying an additional 1,520 shares during the last quarter. Lord Abbett & CO. LLC boosted its holdings in shares of Immunome by 4.1% during the third quarter. Lord Abbett & CO. LLC now owns 450,280 shares of the company’s stock valued at $6,583,000 after acquiring an additional 17,566 shares during the period. Barclays PLC grew its position in shares of Immunome by 125.9% during the third quarter. Barclays PLC now owns 105,886 shares of the company’s stock worth $1,547,000 after acquiring an additional 59,016 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Immunome by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after acquiring an additional 144,557 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Immunome in the 3rd quarter worth about $363,000. Institutional investors own 44.58% of the company’s stock.

Insider Buying and Selling

In other news, CEO Clay B. Siegall purchased 66,057 shares of the stock in a transaction dated Thursday, November 21st. The shares were bought at an average cost of $9.54 per share, for a total transaction of $630,183.78. Following the transaction, the chief executive officer now owns 485,693 shares in the company, valued at $4,633,511.22. This trade represents a 15.74 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO Philip Tsai acquired 21,000 shares of the business’s stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.43 per share, with a total value of $198,030.00. Following the acquisition, the chief technology officer now owns 21,000 shares of the company’s stock, valued at approximately $198,030. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 102,862 shares of company stock valued at $978,045 over the last quarter. Corporate insiders own 8.60% of the company’s stock.

Immunome Stock Up 0.4 %

Shares of NASDAQ:IMNM opened at $10.21 on Thursday. The company has a 50 day moving average of $11.33 and a 200-day moving average of $12.87. Immunome, Inc. has a twelve month low of $8.97 and a twelve month high of $30.96.

Analysts Set New Price Targets

A number of research analysts have issued reports on IMNM shares. Stephens started coverage on shares of Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Monday, January 13th. Finally, Piper Sandler lowered their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $28.83.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.